ChemoTech has a very competent management and Board of Directors with extensive expertise and substantial experience of medical research and clinical work, as well as of the international healthcare industry.
Company Management
Born 1957. Chairman of the Board of Directors since 2020.
Independent in relation to the Company and its management but independent in relation to major shareholders..
Education and experience: M.Sc. Chemical Engineering, Chalmers University of Technology, PhD Department of Pure and Applied Biochemistry, Lund Institute of Technology, University of Lund. Lars has 30 years’ experience from leading positions in life science companies. A large part of his career has involved research and development at for example AstraZeneca but Lars also has a vast experience in founding, running and developing companies in life science.
Current assignments: Chairman of the board of Strominnate AB, board member of Asgard Therapeutics AB, Chosa Oncology AB (publ), Cell Invent AB and Xintela AB (publ). Partner at Ventac Partners.
Previous assignments (last five years): CEO of Idogen AB (publ), Acting CEO of Pharmiva AB (publ), Chairman of the board of IAmPatient AB, board member of Hamlet Pharma AB (publ), alternate board member of CanImGuide AB and Immodulate AB.
Lars Hedbys holds 9 709 B-shares and 8 427 TO3 via company.
Born 1974. Member of the Board of Directors and CEO since 2015.
Not independent in relation to the Company and, being the Company´s largest shareholder, not independent in relation to major shareholders.
Education and experience: BA, Marketing, Management, Lund University. 20 years’ experience as market manager, sales manager and Board member of life science companies. Has among other things held positions in Arjo AB, Getinge, Navigator Communications, Insulution AB, OnMeD and SYSMEX.
Current assignments: Chairman of Scandinavian MediTech (Indian subsidiary), Fricks Property & Equity Invest AB.
Previous assignments (last five years): Member of the Board of Directors of Insulution AB 2009-2011, Onmed International 2012-March 2013, Onmed India Private Limited 2011-June 2014. Member of the Advisory Board for Billion Minds Foundation 2009-2014.
Mohan Frick holds 665,000 A-shares, 248,979 B-shares, direct or via company.
Born 1953. Member of the Board of Directors since 2020.
Independent of the Company and independent of major shareholders.
Education and experience: Royal Institute of Technology; M.Sc. in Biochemistry & Biotechnology. Extensive experience from Life Science Industry. Scientific and Product Development management roles in LKB/Pharmacia Biotech/Amersham-Pharmacia Biotech. Co-founder and VP R&D of Gyros AB, CVP/CSO of Dako-Agilent A/S, Boardmember of Biomonitor A/S.
Current assignments: CSO of Immunovia AB, Boardmember of Gradientech AB, Boardmember of Fluimedix A/S, CEO and owner of Reomics AB, Partner in Ventac Partners, Partner in Ventac Capital
Previous assignments (last five years): –
Rolf Ehrnström holds 20,000 B-shares direct or via company.
Born 1973. Member of the Board of Directors since 2020
Independent of the Company and independent of major shareholders.
Education and experience: B.Sc. in Business Administration from the State University of New York. Has also studied at Uppsala University’s renowned Institution for Peace and Conflict Studies for his own interest. Robin Sukhia has worked with India since 1996. Through a Swedish Venture Capital firm, he was one of the pioneers in northern Europe to invest into India. He has held board positions in India and Sweden and since 2005.
Current assignments: Secretary General and President of the Sweden-India Business Council (SIBC), Secretariat to ISBLRT – India Sweden Business Leaders’ Roundtable
Previous assignments: Special Advisor at Risk Mitigation firm Vesper Group, which is Swedens primary company on advising corporates on security and protection in high risk countries.
Robin Sukhia holds 15,000 B-shares.
Born 1959.
Education and experience: M.Sc. in Chemical Engineering and PhD at Faculty of Engineering, Lund University. More than 30 years of experience from medical devices, Biotech, electrical-mechanical products and chemical processes in roles such as Director Environmental Laboratory, Quality Director, and QA/RA specialist consultant. She has held positions in Pharmiva AB, Camurus AB, GS-development (Sandberg development) and now has her own consulting business Astrad AB.
Eva Ståhl Wernersson holds 15,000 B-shares.
Born 1953. Member of the Board of Directors since 2020.
Independent of the Company and independent of major shareholders.
Education and experience: Degree from Royal Institute of Technology (KTH) in Stockholm. Formerly President Whirlpool Europe, CEO Duni AB, President Fujitsu Nordic and Director at Bofors AB.
Current assignments: Chairman of QleanAir AB and Nordic Flanges AB. Board member of Directors of Bure Equity AB, Scanfil OY, ScandiNova Systems AB, KTH Executive School AB, Real Holding AB. CEO of BEngström AB and BEngström Förvaltning AB.
Previous assignments (last five years): Opticos AB, Scandinavian Executive AB, Advania AB, Prevas AB, Crem International AB, Chambers Group AB, Scanfil Sweden AB and Partnertech AB.
Bengt Engström holds 49,400 B-shares direct or via company.
Born 1975. Member of the Board between august 2015 – June 2019 and again since May 2021.
Not independent in relation to the Company and being one of the Company´s largest shareholders, not independent in relation to major shareholders.
Education and experience: Master of Business and Science, Finance, Lund University. 20 years’ banking experience with main focus on market making and trading credit risk.
Current assignments: Working within family office.
Previous assignments (last five years): Execution Trader, Fixed Income, Robur, 2018-2020. Member of the Board, Scandinavian Chemotech AB, 2015-2019. Chief Dealer, Head of Credit Trading Sweden, Credit Trading and Complex Risk, Nordea, 2007-2017.
Martin Jerndal holds 594,704 B-shares direct or indirect via closest family.
Born 1966.
Education and experience: Studies in economics at Lund University and Malmö University. 35 years of experience, from various positions within finance departments in several companies of various sizes, for example Safegate International AB, KPMG and Accountor. Also experiences as a consultant, amongst others, Massive Entertainment and Modity Energy Trading via own company.
Current assignments: Part owner and chairman of the board Rönneholm Management AB
Ann Ohlsson holds 3,000 B-shares.
Born 1974.
Education and experience: Medical graduation from the Government Medical College, Srinagar. He completed his Pathology residency at the National Board of Examinations and Translational Medicine training at the University of Edinburgh.
Current assignments: Academic Director at the James Lind Institute in Switzerland.
Previous assignments (last five years): Senior Director & Head of Clinical Development at Piramal Enterprises NCE Research, Associate Director for Life Sciences at Cognizant Technology Solutions, Vice President for R&D at Venus Medicine Research Centre, and the Director for Translational Medicine and Therapeutics at HealthCare Global Enterprises Ltd (HCG Oncology).